Algorithmiq
About
Algorithmiq develops quantum algorithms and software for drug discovery and pharmaceutical research, focusing on quantum-enhanced molecular simulation and optimization techniques.
November 12, 2025: Unveiled Quantum Advantage Tracker in collaboration with IBM Quantum and leading theorists at IBM's Quantum Developer Conference in Atlanta. First verified quantum simulation outperforming classical methods. CEO Sabrina Maniscalco: 'We are no longer chasing a single moment of quantum advantage. We are building an experiment that never really ends.' The living record tracks quantum and classical progress where results are published, verified, and challenged. Partners: IBM, Algorithmiq, Flatiron Institute, BlueQubit.
In February 2025, partnered with Quantum Circuits to leverage the Aqumen Seeker full-stack quantum computing system featuring industry-first dual-rail qubits with built-in error detection for more accurate chemistry calculations. $15 million Series A (2023) + $4 million seed, backed by Tiger Global and European Investment Bank.
Market positioning: leading quantum drug discovery company with IBM partnership and first verified quantum simulation advantage.
Categories
Key People
Sabrina Maniscalco (Co-founder, CEO), Stefan Filipp (Co-founder, CTO)
Request Information
Interested in Algorithmiq? Get pricing, demos, or technical details.
Request Information
Get in touch with Algorithmiq about your project.
Claim This Profile
Are you from Algorithmiq? Verify your association to update your listing and receive notifications.
Claim Your Profile
Verify you represent Algorithmiq to update your listing.
Quick Facts
Links
Location
Loading map...
Stay Updated
Get the latest quantum computing news delivered to your inbox.